Cipla signs exclusive 5-year marketing deal with Pfizer for 4 brands

Strategic Transactions View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹1496.90

prior close

₹1506.30

announcement price

In-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.6%+0.6% vs market

Pharmaceuticals peers, median of 153sector+0.6%+0.6% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty 100 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.1

15m

-0.1

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2+0.6+0.6+0.6+0.6

Next day

+0.9+1.4-0.5+1.3-0.4

+0.3+1.5-1.2+1.4-1.1

-0.1+1.3-1.4+1.4-1.6

+0.5+1.0-0.5+0.7-0.3

-0.3+0.6-0.9+0.0-0.3

+0.7+1.4-0.6+0.7+0.1

15d

-2.2+0.1-2.3-1.0-1.2

-7.3-0.5-6.7-1.8-5.5

-11.2-0.9-10.3-3.9-7.3

-16.8-10.2-6.7-10.1-6.8

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cipla signed a 5-year exclusive Supply and Marketing Agreement with Pfizer to market and distribute four brands in India: Corex cough syrup, Dolonex painkiller, Neksium acid reflux drug and Dalacin C antibiotic. Cipla gets sole rights to sell these in India while Pfizer continues manufacturing them. No upfront cash paid by either side. The deal uses Cipla's wide distribution network to boost reach of these well-known Pfizer brands.

Likely market impact

Adds four established Pfizer brands to Cipla's portfolio at no upfront cost, strengthening presence in respiratory, pain, gastro and anti-infective segments.